Browsing by Author "Eriksson, M"

Now showing 1 - 5 of 5

Sarcoma European and Latin American Network (SELNET) Recommendations on Prioritization in Sarcoma Care During the COVID-19 Pandemic
(Oxford University Press, 2020) Martin-Broto, J; Hindi, N; Aguiar S, Jr; Badilla-González, R; Castro-Oliden, V; Chacón, M; Correa-Generoso, R; de Álava, E; Donati, DM; Eriksson, M; Falla-Jimenez, M; German, G; Gobo Silva, ML; Gouin, F; Gronchi, A; Haro-Varas, JC; Jiménez-Brenes, N; Kasper, B; Lopes de Mello, CA; Maki, R; Martínez-Delgado, P; Martínez-Said, H; Martinez-Tlahuel, JL; Morales-Pérez, JM; Muñoz-Casares, FC; Nakagawa, SA; Ortiz-Cruz, EJ; Palmerini, E; Patel, S; Moura, DS; Stacchiotti, S; Sunyach, MP; Valverde, CM; Waisberg, F; Blay, JY
Background: The COVID‐19 outbreak has resulted in collision between patients infected with SARS‐CoV‐2 and those with cancer on different fronts. Patients with cancer have been impacted by deferral, modification, and even cessation of therapy. Adaptive measures to minimize hospital exposure, following the precautionary principle, have been proposed for cancer care during COVID‐19 era. We present here a consensus on prioritizing recommendations across the continuum of sarcoma patient care. Material and Methods: A total of 125 recommendations were proposed in soft‐tissue, bone, and visceral sarcoma care. Recommendations were assigned as higher or lower priority if they cannot or can be postponed at least 2–3 months, respectively. The consensus level for each recommendation was classified as “strongly recommended” (SR) if more than 90% of experts agreed, “recommended” (R) if 75%–90% of experts agreed and “no consensus” (NC) if fewer than 75% agreed. Sarcoma experts from 11 countries within the Sarcoma European‐Latin American Network (SELNET) consortium participated, including countries in the Americas and Europe. The European Society for Medical Oncology‐Magnitude of clinical benefit scale was applied to systemic‐treatment recommendations to support prioritization. Results: There were 80 SRs, 35 Rs, and 10 NCs among the 125 recommendations issued and completed by 31 multidisciplinary sarcoma experts. The consensus was higher among the 75 higher‐priority recommendations (85%, 12%, and 3% for SR, R, and NC, respectively) than in the 50 lower‐priority recommendations (32%, 52%, and 16% for SR, R, and NC, respectively). Conclusion: The consensus on 115 of 125 recommendations indicates a high‐level of convergence among experts. The SELNET consensus provides a tool for sarcoma multidisciplinary treatment committees during the COVID‐19 outbreak.
SELNET clinical practice guidelines for bone sarcoma
(Elsevier Ireland Ltd, 2022) Blay, JY; Palmerini, E; Bollard, J; Aguiar, S; Angel, M; Araya, B; Badilla, R; Bernabeu, D; Campos, F; Carvajal-Montoya, A; Casavilca-Zambrano, S; Castro-Oliden, Víctor; Chacón, M; Clara-Altamirano, MA; Collini, P; Correa-Genoroso, R; Costa, FD; Cuellar, M; dei Tos, AP; Dominguez-Malagon, HR; Donati, DM; Dufresne, A; Eriksson, M; Farias-Loza M; Frezza, AM; Frisoni, T; Garcia-Ortega, DY; Gerderblom, H; Gouin, F; Gómez-Mateo, MC; Gronchi, A; Haro, J; Hindi, N; Huanca, L; Jimenez, N; Karanian, M; Kasper, B; Lopes, A; Lopes David, BB; Lopez-Pousa, A; Lutter, G; Maki, RG; Martinez-Said, H; Martinez-Tlahuel, JL; Mello, CA; Morales-Pérez, JM; Moura, DS; Nakagawa, SA; Nascimento, AG; Ortiz-Cruz, EJ; Patel, S; Pfluger, Y; Provenzano, S; Righi, A; Rodriguez, A; Santos, TG; Scotlandi, K; Soulé, T; Stacchiotti, S; Valverde, CM; Waisberg, F; Zamora-Estrada, E; Martin-Broto, J
Bone sarcoma are infrequent diseases, representing < 0.2% of all adult neoplasms. A multidisciplinary management within reference centers for sarcoma, with discussion of the diagnostic and therapeutic strategies within an expert multidisciplinary tumour board, is essential for these patients, given its heterogeneity and low frequency. This approach leads to an improvement in patient's outcome, as demonstrated in several studies. The Sarcoma European Latin-American Network (SELNET), aims to improve clinical outcome in sarcoma care, with a special focus in Latin-American countries. These Clinical Practice Guidelines (CPG) have been developed and agreed by a multidisciplinary expert group (including medical and radiation oncologist, surgical oncologist, orthopaedic surgeons, radiologist, pathologist, molecular biologist and representatives of patients advocacy groups) of the SELNET consortium, and are conceived to provide the standard approach to diagnosis, treatment and follow-up of bone sarcoma patients in the Latin-American context. © 2022 The Authors
SELNET clinical practice guidelines for bone sarcoma
(Elsevier Ireland Ltd, 2022) Blay, JY; Palmerini, E; Bollard, J; Aguiar, S; Angel, M; Araya, B; Badilla, R; Bernabeu, D; Campos, F; Chs, CS; Carvajal Montoya, A; Casavilca-Zambrano, S; Castro-Oliden, V; Chacón, M; Clara-Altamirano, MA; Collini, P; Correa Genoroso, R; Costa, FD; Cuellar, M; Dei Tos, AP; Dominguez Malagon, HR; Donati, DM; Dufresne, A; Eriksson, M; Farias-Loza, M; Frezza, AM; Frisoni, T; Garcia-Ortega, DY; Gerderblom, H; Gouin, F; Gómez-Mateo, MC; Gronchi, A; Haro, J; Hindi, N; Huanca, L; Jimenez, N; Karanian, M; Kasper, B; Lopes, A; Lopes David, BB; Lopez-Pousa, A; Lutter, G; Maki, RG; Martinez-Said, H; Martinez-Tlahuel, JL; Mello, CA; Morales Pérez, JM; Moura, DS; Nakagawa, SA; Nascimento, AG; Ortiz-Cruz, EJ; Patel, S; Pfluger, Y; Provenzano, S; Righi, A; Rodriguez, A; Santos, TG; Scotlandi, K; Mlg S, Soulé T; Stacchiotti, S; Valverde, CM; Waisberg, F; Zamora Estrada, E; Martin-Broto, J
Bone sarcoma are infrequent diseases, representing < 0.2% of all adult neoplasms. A multidisciplinary management within reference centers for sarcoma, with discussion of the diagnostic and therapeutic strategies within an expert multidisciplinary tumour board, is essential for these patients, given its heterogeneity and low frequency. This approach leads to an improvement in patient's outcome, as demonstrated in several studies. The Sarcoma European Latin-American Network (SELNET), aims to improve clinical outcome in sarcoma care, with a special focus in Latin-American countries. These Clinical Practice Guidelines (CPG) have been developed and agreed by a multidisciplinary expert group (including medical and radiation oncologist, surgical oncologist, orthopaedic surgeons, radiologist, pathologist, molecular biologist and representatives of patients advocacy groups) of the SELNET consortium, and are conceived to provide the standard approach to diagnosis, treatment and follow-up of bone sarcoma patients in the Latin-American context.
SELNET clinical practice guidelines for soft tissue sarcoma and GIST
(W.B. Saunders Ltd, 2022) Blay, JY; Hindi, N; Bollard, J; Aguiar, S Jr; Angel, M; Araya, B; Badilla, R; Bernabeu, D; Campos, F; Caro-Sánchez, CHS; Carvajal, B; Carvajal Montoya, A; Casavilca-Zambrano, S; Castro-Oliden, V; Chacón, M; Clara, M; Collini, P; Correa Genoroso, R; Costa, FD; Cuellar, M; Dei Tos, AP; Dominguez Malagon, HR; Donati, D; Dufresne, A; Eriksson, M; Farias-Loza, M; Fernandez, P; Frezza, AM; Frisoni, T; Garcia-Ortega, DY; Gelderblom, H; Gouin, F; Gómez-Mateo, MC; Gronchi, A; Haro, J; Huanca, L; Jimenez, N; Karanian, M; Kasper, B; Lopes David, BB; Lopez-Pousa, A; Lutter, G; Martinez-Said, H; Martinez-Tlahuel, J; Mello, CA; Morales Pérez, JM; Moura David, S; Nascimento, AG; Ortiz-Cruz, EJ; Palmerini, E; Patel, S; Pfluger, Y; Provenzano, S; Righi, A; Rodriguez, A; Salas, R; Santos, TTG; Scotlandi, K; Soule, T; Stacchiotti, S; Valverde, C; Waisberg, F; Zamora Estrada, E; Martin-Broto, J
Soft tissue sarcoma (STS) and gastrointestinal tumors (GIST) encompass > 80 different histologic subtypes. Clinical practice guidelines for STS and GIST still lack in Latin-American countries. Tailored clinical guidelines are instrumental to improve outcome in sarcoma patients in LatinAmerican countries. This is the first review establishing STS and GIST guidelines for the purpose of LatinAmerican clinical practices to our knowledge.
SELNET clinical practice guidelines for soft tissue sarcoma and GIST
(W.B. Saunders Ltd, 2022) Blay, JY; Hindi, N; Bollard, J; Aguiar, S; Angel, M; Araya, B; Badilla, R; Bernabeu, D; Campos, F; Caro-Sánchez, CHS; Carvajal, B; Carvajal Montoya, A; Casavilca-Zambrano, S; Castro-Oliden V; Chacón, M; Clara, M; Collini, P; Correa-Genoroso, R; Costa, FD; Cuellar, M; dei Tos, AP; Dominguez Malagon, HR; Donati, A; Dufresne, A; Eriksson, M; Farias-Loza, M; Fernandez, P; Frezza, AM; Frisoni, T; Garcia-Ortega, DY; Gelderblom, H; Gouin, F; Gómez-Mateo, MC; Gronchi, A; Haro, J; Huanca, L; Jimenez, N; Karanian, M; Kasper, B; Lopes David, BB; Lopez-Pousa, A; Lutter, G|Martinez-Said, H; Martinez-Tlahuel, J; Mello, CA; Morales-Pérez, JM; Moura-David, S; Nascimento, AG; Ortiz-Cruz, EJ; Palmerini, E; Patel, S; Pfluger, Y; Provenzano, S; Righi, A; Rodriguez, A; Salas, R; Santos, TTG; Scotlandi, K; Soule, T; Stacchiotti, S; Valverde, C; Waisberg, F; Zamora Estrada, E; Martin-Broto, J
Soft tissue sarcoma (STS) is a heterogeneous group of neoplasms, encompassing > 80 different histologic subtypes. Approximately three quarter of sarcoma arise from soft-tissue, about 15% are gastrointestinal stromal tumours (GISTs) and bone sarcoma represent the remaining 10%. The current guidelines will focus on soft-tissue and GIST, excluding Kaposi sarcoma and non-pleomorphic rhabdomyosarcoma. Bone sarcomas are covered in a different paper.